FDA-Approved Radiopharmaceuticals for Cancer Therapy
The FDA has approved several radiopharmaceuticals for cancer therapy, with the most clinically significant being Lutetium-177 (Lu-177) DOTATATE for neuroendocrine tumors, Lu-177 PSMA-617 for metastatic castration-resistant prostate cancer, and Radium-223 dichloride for bone-metastatic prostate cancer.
Currently Approved Radiopharmaceuticals and Standard Dosing
Lutetium-177 DOTATATE (Lutathera®)
- Indication: Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) 1
- FDA Approval: 2018 1
- Standard Dosing: 7.4 GBq (200 mCi) administered intravenously every 8 weeks for a total of 4 cycles 2
- Clinical Impact: The NETTER-1 trial demonstrated a 79% reduction in risk of disease progression in midgut NETs 3
Lutetium-177 PSMA-617 (Pluvicto®)
- Indication: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with androgen receptor-directed therapy and taxane-based chemotherapy 4
- FDA Approval: March 2022 1
- Standard Dosing: 7.4 GBq (200 mCi) administered intravenously every 6 weeks for 4-6 cycles 4, 2
- Patient Selection Criteria: Requires ≥1 PSMA-positive lesion with no dominant PSMA-negative metastatic lesions (defined as bone lesions with soft tissue ≥1.0 cm, lymph nodes ≥2.5 cm in short axis, or solid organ metastases ≥1.0 cm) 4
- Clinical Impact: The VISION trial showed a 38% reduction in risk of death, with median overall survival of 15.3 vs 11.3 months compared to standard care alone 4, 3
Radium-223 Dichloride (Xofigo®)
- Indication: Symptomatic bone metastases from castration-resistant prostate cancer with no known visceral metastatic disease 5
- FDA Approval: May 2013 5
- Standard Dosing: 55 kBq/kg (1.49 microcuries/kg) body weight administered as 6 monthly intravenous injections 5
- Clinical Impact: The ALSYMPCA trial demonstrated improved overall survival (14.9 vs 11.3 months; HR 0.70) and prolonged time to first skeletal-related event (15.6 vs 9.8 months) 5
- Critical Safety Note: Must be used with concurrent bone-protecting agents (denosumab or zoledronic acid) when combined with androgen receptor-directed therapy to prevent pathological fractures, as demonstrated by the ERA 223 trial 4
Older Palliative Radiopharmaceuticals
Strontium-89 and Samarium-153
- Indication: Palliation of multifocal bone pain from widespread bone metastases in prostate cancer 6
- Limitation: Role traditionally limited to pain palliation only; bone marrow toxicity makes repeated treatments problematic and no survival benefit demonstrated 7
- Clinical Status: Largely superseded by Radium-223, which provides survival advantage rather than just palliation 5
Iodine-131
- Indication: Thyroid follicular carcinoma with bone metastases 7
- Status: Well-established treatment for this specific indication
Key Clinical Considerations
Dosimetry Requirements
Current regulatory standards (RD601/2019) mandate that all radiotherapeutic exposures be individually planned and verified, with doses to non-target volumes kept as low as reasonably achievable 2. However, in practice, both Lu-177 agents are administered using fixed activity protocols rather than individualized dosimetry-based planning 2.
Emerging Alpha-Particle Therapies
Alpha-emitting radioisotopes (Actinium-225, Lead-212) are under investigation and show promise for overcoming beta-particle resistance due to their high linear energy transfer and greater cytotoxicity in radioresistant tumors 3, 8. These are not yet FDA-approved but represent the next generation of targeted radionuclide therapy.
Common Toxicities
- Lu-177 agents: Anemia, thrombocytopenia, lymphopenia, and fatigue are the most significant grade ≥3 adverse events 4
- Radium-223: Low hematologic toxicity (3% neutropenia, 6% thrombocytopenia, 13% anemia) with mild GI effects (nausea, diarrhea, vomiting) due to fecal elimination 5
Imaging Companion Diagnostics
- For Lu-177 DOTATATE: Gallium-68 DOTATATE PET/CT for patient selection
- For Lu-177 PSMA-617: FDA-approved Gallium-68 PSMA-11 PET/CT; panel consensus supports equivalency of F-18 piflufolastat PSMA and F-18 flotufolastat PSMA 4